WallStSmart

Co-Diagnostics, Inc. Common Stock (CODX)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 877617% more annual revenue ($6.30B vs $718,170). EW leads profitability with a 17.4% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 61/100 (C+).

CODX

Hold

38

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 5.0Quality: 5.5
Piotroski: 1/9Altman Z: -5.19

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 6.0Quality: 8.5
Piotroski: 3/9Altman Z: 4.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CODX.

EWUndervalued (+68.7%)

Margin of Safety

+68.7%

Fair Value

$253.29

Current Price

$85.96

$167.33 discount

UndervaluedFair: $253.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CODX4 strengths · Avg: 9.3/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
190.3%10/10

Revenue surging 190.3% year-over-year

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
30.8%8/10

Earnings expanding 30.8% YoY

EW4 strengths · Avg: 9.5/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

Areas to Watch

CODX4 concerns · Avg: 2.8/10
Market CapQuality
$20.75M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Return on EquityProfitability
-302.3%2/10

ROE of -302.3% — below average capital efficiency

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.054/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
46.0x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : CODX

The strongest argument for CODX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 190.3% demonstrates continued momentum.

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bear Case : CODX

The primary concerns for CODX are Market Cap, Profit Margin, Piotroski F-Score.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.

Key Dynamics to Monitor

CODX profiles as a hypergrowth stock while EW is a growth play — different risk/reward profiles.

CODX carries more volatility with a beta of 1.26 — expect wider price swings.

CODX is growing revenue faster at 190.3% — sustainability is the question.

CODX generates stronger free cash flow (-8M), providing more financial flexibility.

Bottom Line

EW scores higher overall (61/100 vs 38/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Co-Diagnostics, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Co-Diagnostics, Inc., a molecular diagnostic company, develops, manufactures, and sells reagents used for diagnostic tests that function by detecting and / or analyzing nucleic acid molecules. The company is headquartered in Salt Lake City, Utah.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?